New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2013
11:55 EDTJNY, AZN, EZCH, ARRS, SNTAHigh option volume stocks: SNTA EZCH JNY ARRS AZN
News For SNTA;EZCH;JNY;ARRS;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 14, 2014
14:53 EDTAZNCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
07:14 EDTAZNAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
07:16 EDTAZNBIT Congress to hold a conference
Subscribe for More Information
07:03 EDTAZNAstraZeneca initiates development program for Brilinta reversal agent
Subscribe for More Information
05:34 EDTAZNAstraZeneca, Isis Pharmaceuticals to co-develop oligonucleotide delivery methods
Subscribe for More Information
November 12, 2014
11:34 EDTEZCHEZchip: Q4 Tilera revenue to be in $22M-$24M range
11:32 EDTEZCHEZchip believes growth from ZTE will resume in the coming quarters
Subscribe for More Information
11:17 EDTAZNLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
10:30 EDTEZCHEZchip expects down cycle to be a 'temporary situation that it will be fixed'
Subscribe for More Information
10:27 EDTEZCHEZchip in down cycle right now, but expects up cycle to come before mid-2015
Subscribe for More Information
10:23 EDTEZCHEZchip sees FY15 OpEx $55M
Subscribe for More Information
10:13 EDTEZCHEZchip expects revenue from Cisco to grow YoY in 2014
Comments taken from Q3 earnings conference call.
09:41 EDTEZCHEZchip: Slowdown in carrier spending is temporary
Subscribe for More Information
08:15 EDTEZCHEZchip reports Q3 non-GAAP EPS 28c, consensus 28c
Subscribe for More Information
07:47 EDTARRSARRIS sell-off on net neutrality concerns seems overdone, says Stephens
Subscribe for More Information
07:45 EDTARRSARRIS should be bought on weakness, says RBC Capital
Subscribe for More Information
07:35 EDTAZNAdvaxis submits IND application for ADXS-HPV Phase 1/2 study, MEDI4736
Advaxis (ADXS) announced that the company has submitted an Investigational New Drug application, or IND, to the FDA to conduct a Phase 1/2 study of ADXS-HPV alone or in combination with MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, for the treatment of advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. This follows the press release issued in July announcing the clinical trial collaboration between Advaxis and MedImmune, the global biologics research and development arm of AstraZeneca (AZN).
November 11, 2014
16:05 EDTAZNAmgen, AstraZeneca say Phase 3 brodalumab study met endpoints
Subscribe for More Information
15:43 EDTAZNLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
November 10, 2014
15:55 EDTARRSNeedham to hold a conference
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use